<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544232</url>
  </required_header>
  <id_info>
    <org_study_id>GBG 49</org_study_id>
    <nct_id>NCT00544232</nct_id>
  </id_info>
  <brief_title>Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)</brief_title>
  <official_title>Randomized Comparison of a Preoperative, Dose-Intensified, Interval-Shortened, Sequential Chemotherapy With Epirubicin, Paclitaxel and CMF ± Darbepoetin Alfa Versus a Preoperative, Sequential Chemotherapy With Epirubicin and Cyclophosphamide Followed by Paclitaxel in Standard Dosage ± Darbepoetin Alfa in Patients With Primary Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Breast Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmacia</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>German Breast Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present clinical trial will investigate the efficacy of a sequential interval-shortened
      and dose-intensified preoperative use of epirubicin, paclitaxel and CMF with preoperative
      sequential administration of epirubicin and cyclophosphamide followed by paclitaxel in breast
      cancer. In addition, the influence of darbepoetin alfa on the response rate and quality of
      life is to be investigated in both treatment arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arm A: Sequential treatment in standard doses with Epirubicin (90 mg/m2)/cyclophosphamide
      (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×.

      Pegfilgratim should be used as secondary preventive after febrile neutropenia in the standard
      arm of the study, or in exceptional cases also after severe febrile neutropenia necessitating
      postponement of the treatment by more than one week ± Darbepoetin alfa 1 × 4.5 µg/kg of body
      weight every two weeks with the start of the first epirubicin dose (day 1) until 14 days
      after the last dose of paclitaxel Daily oral intake of 200 mg iron unless there complications
      occur with taking iron

      Arm B: sequential dose-intensified, interval-shortened treatment with Epirubicin (150 mg/m2)
      d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF (600/40/600
      mg/m2) d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg after epirubicin and/or paclitaxel:
      subcutaneous injection on day 2. After CMF pegfilgrastim should be used as a secondary
      preventive measure

      ± Darbepoetin alfa 1 × 4.5 µg/kg of body weight every two weeks with the start of the first
      dose of epirubicin (day 1) until 14 days after the last dose of CMF Daily oral dose of 200 mg
      iron unless complications occur in taking iron.

      Primary goal: Determining the relapse-free survival time and overall survival after
      dose-intensified sequential preoperative chemotherapy including anthracycline and taxan
      and/or after preoperative chemotherapy including anthracycline followed by taxan in a
      standard dose
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free survival time and overall survival</measure>
    <time_frame>2007</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">720</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>epirubicin, paclitaxel and CMF +/- darbepoetin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×
+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EC followed by paclitaxel +/- darbepoetin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF
+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa</intervention_name>
    <description>Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×
+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel</description>
    <arm_group_label>epirubicin, paclitaxel and CMF +/- darbepoetin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa</intervention_name>
    <description>Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF
+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF</description>
    <arm_group_label>EC followed by paclitaxel +/- darbepoetin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed breast cancer: at least three fast biopsies.

          -  Primary tumor ≥2 cm acc. to clinical measurement or manifestation of an inflammatory
             breast cancer.

          -  No systemic metastasis, exclusion by chest x-ray, sonogram of the upper abdomen and
             skeletal scintiscan.

          -  Age ≥18 years and ≤65 years.

          -  ECOG &lt; 2/WHO 0-1

          -  Adequate organ function defined as SGOT and bilirubin ≤ 1.5× upper limit WBC ≥ 3000
             /µL Neutrophils ≥ 1000 /µL Platelets ≥ 100,000 /µL Serum creatinine &lt; 2.0 mg/dL

          -  Unremarkable heart echo

          -  No florid hepatitis

          -  Written consent to participate in the treatment optimization protocol

        Exclusion Criteria:

          -  Multicentricity in various quadrants (contact the study office)

          -  Known allergy to E. coli-produced medication

          -  Known allergy to medication containing cremophor (e.g., cyclosporin A)

          -  Patients receiving immunosuppressant therapy

          -  Lack of consent after informing the patient

          -  Lack of willingness to keep and disclose personal medical data as part of the study

          -  Pregnancy, nursing

          -  Secondary malignancy, excluding basalioma of the skin or carcinoma in situ of the
             cervix that has received curative therapy

          -  Pre-existing treatment-resistant cardiac disease, coronary heart disease, arrhythmias,
             cardiac insufficiency

          -  Patients with uncontrolled hypertension (diastolic &gt;95 mmHg)

          -  A history of convulsions

          -  Known hypersensitivity to darbepoetin alfa or any of its other ingredients or a known
             hypersensitivity to r-HuEPO
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Untch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic of the Ludwig-Maximilian-University, München</affiliation>
  </overall_official>
  <results_reference>
    <citation>Untch M, Fasching PA, Konecny GE, von Koch F, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Schuster T, Nekljudova V, Lebeau A, Loibl S, von Minckwitz G; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery. Ann Oncol. 2011 Sep;22(9):1988-98. doi: 10.1093/annonc/mdq709. Epub 2011 Mar 8.</citation>
    <PMID>21385882</PMID>
  </results_reference>
  <results_reference>
    <citation>Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Beckmann MW, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Nekljudova V, Lebeau A, Loibl S, Fasching PA; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis. Ann Oncol. 2011 Sep;22(9):1999-2006. doi: 10.1093/annonc/mdq713. Epub 2011 Mar 7.</citation>
    <PMID>21382868</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2007</study_first_submitted>
  <study_first_submitted_qc>October 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <last_update_submitted>February 12, 2016</last_update_submitted>
  <last_update_submitted_qc>February 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>neoadjuvant therapy</keyword>
  <keyword>pCR rates</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

